Current Status of Polio Eradication in India
The PEC expressed satisfaction on the progress made by
Global Polio Eradication Initiative (GPEI) in India in the last one year,
especially on the epidemiology of type 1 wild poliovirus (WPV), by the
intensive use of monovalent OPV type 1 (mOPV1). However, failure to
completely interrupt its transmission and persistence of intense
transmission of type 3 WPV in western UP and Bihar are still causes for
concern. PEC believes that 2010 is a crucial year for polio eradication in
India - by achieving good control over transmission of type 1, GPEI is
within striking distance of interrupting its transmission. According to
the ‘four-year’ cycle, a type 1 polio outbreak is due in 2010, but it
should not be allowed to happen. With the availability of bivalent OPV (bOPV)
against types 1 and 3, type 3 WPV can also be drastically controlled,
simultaneously. While mOPV1 is a sharper tool against WPV 1, bOPV seems to
be adequate against WPV 3; hence there may not be any more need for mOPV3.
Thus, the key to success lies in intelligent and imaginative use of the
three OPVs, i.e. mOPV1, bOPV and tOPV, against WPV types 1 and 3, and
circulating Vaccine Derived Polio Virus (cVDPV) types 1, 2 and 3. At the
same time, PEC advocates the need of having a "plan B" ready in case the
current strategy fails to achieve elimination of WPV type 1 by the end of
this year. Serious consideration should be given to a contingency plan to
use IPV in endemic areas, as recommended earlier by PEC(1) if all other
efforts fail to achieve target. PEC also recommends a special drive for
environmental sanitation and for high routine immunization coverage for
the targeted 107 blocks of Uttar Pradesh (UP) and Bihar marked as
‘high-risk’ by the National Polio Surveillance Project (NPSP).
OPV-induced Gut Immunity and Role of Fully Immunized Older Children in
Sustaining WPV Transmission
Recently, NPSP has documented WPV 1 infection and fecal
shedding of virus among a small proportion of older children who are close
contacts of under-5 children with polio. PEC believes that OPV had failed
to provide adequate herd effect; ‘contact immunization’ due to widespread
transmission of vaccine viruses of OPV had proved to be a myth, especially
in endemic regions. The phenomenon that vaccinated and (themselves)
protected children may play a role in spreading WPVs is known for many
decades and is widely accepted in India, but not by the international
experts. Mucosal immunity induced by OPV is not only ineffective against
WPV infection, but it also wanes over time. Furthermore, mucosal immunity
is better when vaccine efficacy is high, and ultimately it more closely
correlates with the titer of homologous humoral antibody than its mere
presence. Protection from disease and mucosal immunity do not necessarily
parallel each other. OPV’s efficacy is low and the force of transmission
of WPV is very high in Northern India, resulting in imbalance between
humoral and mucosal immunity on the one hand and with the force of WPV
transmission on the other.
However, the issue related to immunized older children
facilitating wild virus transmission needs to be studied further before
taking any remedial measures to address that. PEC believes that the
question, "how significant is the contribution of imperfect gut mucosal
immunity to the persistence of transmission in these areas?" needs further
evaluation. If studies confirm significant contribution of both the waning
mucosal immunity and OPV-vaccinated children responsible for sustaining
circulation of WPVs, strategies to boost mucosal immunity may be urgently
required. The role of IPV (one or preferably two doses) in rapidly
boosting mucosal immunity can be worth considering here instead of
broadening the age of OPV administration, as has been proposed.
Issues Related to Polio Vaccines
Success of the GPEI in India depends on how efficiently
and intelligently all the available vaccines against polio are utilized.
The current research by ICMR/GPEI has failed to show an adequate serocon-version
with birth dose of mOPV1 given on the day of birth (0 day). Based on the
evaluation of all the study findings, it suggests an alternate approach:
achieve high coverage with tOPV at birth (avoiding days 0-2), 6 weeks, 10
weeks, 14 weeks, and 15 to 18 months. PEC advocates bOPV for all
Supplementary Immunization Activity (SIAs) with the number of National
Immunization Days (NIDs) fixed as 3 in the lowest season; strategic use of
IPV to improve gut immunity in highly endemic regions; and, introduction
of IPV in routine immunization in southern states free of wild polio, to
facilitates OPV cessation.
VAPP and Circulating VDPV
PEC expressed surprise on continuous neglect and
disregard shown to Vaccine Associated Polio Paralysis (VAPP) while cVDPV
(essentially a form of the former) cases were acknowledged. PEC reiterates
its demand of having more transparency on the issue of VAPP. It urges the
NPSP to list VAPP cases along with the wild poliovirus and cVDPV cases in
the final tally.
Though cVDPV may not be a problem as of now, PEC
recommends to the Ministry of Health (MoH)/Government of India (GOI) to
start discussions to plan appropriate strategies and measures to prevent
and pre-empt the outbreaks of cVDPV, especially during post-eradication
era.
RI and UIP Reinforcement
PEC believes that re-building universal immunization
program (UIP) in several states has to be undertaken as an immediate
priority, irrespective of the turns of events pertaining to polio
eradication. It urges the MoH/GOI to urgently identify reasons why
coverage is still low in key districts of UP. If reasons like staff
shortages, vaccine shortages, and inconvenient sessions for families, are
found, they should be remedied at the earliest. There is an urgent need to
establish a disease surveillance system within UIP. PEC requests MoH to go
through its position paper published earlier on how to reform and rebuild
UIP in India(2).
Continued Research and Future Strategies
PEC welcomes the current initiatives of GOI (ICMR)/GPEI
(NPSP) in carrying out many research projects to determine current and
future needs. However, it underlines the need to perform certain studies
especially on mOPV/bOPV in the settings of high WPV endemicity, especially
in western UP and central Bihar to reconfirm the findings of these studies
conducted in polio-free cities. There is a need to study impact of one or
two doses of IPV on mucosal gut immunity in OPV-primed children to rapidly
close waning gut immunity in endemic regions.
Post-eradication Issues
PEC reiterates many of its earlier recommendations on
post-eradication strategies(1). It believes that the time is ripe now to
discuss and plan for the future vaccination strategy rather than waiting
till WPV elimination is achieved. PEC favors the phased introduction of
IPV in the RI programs of southern states where WPV transmission has
already halted years ago, followed gradually by universal use in RI all
over the country (when UP and Bihar are also polio-free). OPV used
thereafter should be confined to three-annual pulses through NIDs, until
we are certain that WPV transmission has truly stopped. PEC believes there
is a need to chalk out a clear strategy on how to deal with the issues
like OPV cessation plans, global synchronization versus regional/national
synchronization, duration of AFP surveillance, tackling of future
outbreaks of both wild and vaccine viruses, role of IPV in controlling
future outbreaks of cVDPVs, development of safe and affordable IPV etc.
PEC thinks that there is a need to develop country-specific economic
models for employing universal IPV during post-eradication era.
References